Cargando…
Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a
Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder caused by heterozygous loss-of-function mutations on the maternal allele of the GNAS gene. Patients with PHP1a predominantly exhibit parathyroid hormone (PTH) resistance and physical features of Albright's hereditary osteodystrophy....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043659/ https://www.ncbi.nlm.nih.gov/pubmed/35497370 http://dx.doi.org/10.1016/j.bonr.2022.101569 |
_version_ | 1784694931017695232 |
---|---|
author | Itoh, Masatsune Okajima, Michiko Kittaka, Yuko Yachie, Akihiro Wada, Taizo Saikawa, Yutaka |
author_facet | Itoh, Masatsune Okajima, Michiko Kittaka, Yuko Yachie, Akihiro Wada, Taizo Saikawa, Yutaka |
author_sort | Itoh, Masatsune |
collection | PubMed |
description | Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder caused by heterozygous loss-of-function mutations on the maternal allele of the GNAS gene. Patients with PHP1a predominantly exhibit parathyroid hormone (PTH) resistance and physical features of Albright's hereditary osteodystrophy. We report two unrelated cases with PHP1a who developed tertiary hyperparathyroidism (HPT). Molecular analyses of the GNAS gene identified a previously known heterozygous 4-bp deletion (c. 565_568delGACT) in exon 7 in case 1 and a novel heterozygous missense mutation (p.Lys233Glu) in exon 9 in case 2. Both patients developed tertiary HPT associated with hyperfunctioning parathyroid glands during long-term treatment of hypocalcemia. Case 1 had severe osteoporosis and underwent parathyroidectomy. Case 2 was asymptomatic with no evidence of bone diseases associated with tertiary HPT. PHP1a patients are at risk of developing tertiary HPT and should be treated with sufficient doses of calcium and vitamin D to achieve serum PTH levels within the mid - normal to double the upper limit of the normal range, regardless of serum calcium levels. |
format | Online Article Text |
id | pubmed-9043659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90436592022-04-28 Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a Itoh, Masatsune Okajima, Michiko Kittaka, Yuko Yachie, Akihiro Wada, Taizo Saikawa, Yutaka Bone Rep Full Length Article Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder caused by heterozygous loss-of-function mutations on the maternal allele of the GNAS gene. Patients with PHP1a predominantly exhibit parathyroid hormone (PTH) resistance and physical features of Albright's hereditary osteodystrophy. We report two unrelated cases with PHP1a who developed tertiary hyperparathyroidism (HPT). Molecular analyses of the GNAS gene identified a previously known heterozygous 4-bp deletion (c. 565_568delGACT) in exon 7 in case 1 and a novel heterozygous missense mutation (p.Lys233Glu) in exon 9 in case 2. Both patients developed tertiary HPT associated with hyperfunctioning parathyroid glands during long-term treatment of hypocalcemia. Case 1 had severe osteoporosis and underwent parathyroidectomy. Case 2 was asymptomatic with no evidence of bone diseases associated with tertiary HPT. PHP1a patients are at risk of developing tertiary HPT and should be treated with sufficient doses of calcium and vitamin D to achieve serum PTH levels within the mid - normal to double the upper limit of the normal range, regardless of serum calcium levels. Elsevier 2022-04-14 /pmc/articles/PMC9043659/ /pubmed/35497370 http://dx.doi.org/10.1016/j.bonr.2022.101569 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Full Length Article Itoh, Masatsune Okajima, Michiko Kittaka, Yuko Yachie, Akihiro Wada, Taizo Saikawa, Yutaka Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
title | Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
title_full | Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
title_fullStr | Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
title_full_unstemmed | Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
title_short | Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
title_sort | tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043659/ https://www.ncbi.nlm.nih.gov/pubmed/35497370 http://dx.doi.org/10.1016/j.bonr.2022.101569 |
work_keys_str_mv | AT itohmasatsune tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a AT okajimamichiko tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a AT kittakayuko tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a AT yachieakihiro tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a AT wadataizo tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a AT saikawayutaka tertiaryhyperparathyroidisminpatientswithpseudohypoparathyroidismtype1a |